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Atypical antipsychotic drugs and risk of ischaemic stroke:
population based retrospective cohort study
Sudeep S Gill, Paula A Rochon, Nathan Herrmann, Philip E Lee, Kathy Sykora, Nadia Gunraj,
Sharon-Lise T Normand, Jerry H Gurwitz, Connie Marras, Walter P Wodchis, Muhammad Mamdani
Abstract
Objective To compare the incidence of admissions to hospital
for stroke among older adults with dementia receiving atypical
or typical antipsychotics.
Design Population based retrospective cohort study.
Setting Ontario, Canada.
Patients 32 710 older adults ( ≥ 65 years) with dementia (17 845
dispensed an atypical antipsychotic and 14 865 dispensed a
typical antipsychotic).
Main outcome measures Admission to hospital with the most
responsible diagnosis (single most important condition
responsible for the patient’s admission) of ischaemic stroke.
Observation of patients until they were either admitted to
hospital with ischaemic stroke, stopped taking antipsychotics,
died, or the study ended.
Results After adjustment for potential confounders,
participants receiving atypical antipsychotics showed no
significant increase in risk of ischaemic stroke compared with
those receiving typical antipsychotics (adjusted hazard ratio
1.01, 95% confidence interval 0.81 to 1.26). This finding was
consistent in a series of subgroup analyses, including ones of
individual atypical antipsychotic drugs (risperidone, olanzapine,
and quetiapine) and selected subpopulations of the main
cohorts.
Conclusion Older adults with dementia who take atypical
antipsychotics have a similar risk of ischaemic stroke to those
taking typical antipsychotics.
Introduction
A variety of behavioural disturbances such as physical
aggression, agitation, hallucinations, and wandering commonly
accompany dementia. The term behavioural and psychological
symptoms of dementia—BPSD—describes this spectrum of non-
cognitive manifestations of dementia.1 The presence of BPSD
can decrease quality of life for patients and caregivers, and
increases the likelihood of the patient being placed in an institu-
tion.2
Treatment of BPSD is challenging. A variety of non-
pharmacological and pharmacological approaches have been
assessed.3 4 Atypical antipsychotics are often prescribed to man-
age BPSD. Although such prescriptions represent off-label
prescribing, this practise is widely endorsed because atypical
antipsychotics are among the best studied treatments for BPSD
and there is a perception that they have fewer adverse effects
than typical antipsychotics.5 6 Recently, however, concerns have
been raised that atypical antipsychotics may increase the risk of
cerebrovascular adverse events, including stroke, among older
adults with BPSD.
In October 2002, Health Canada and Janssen-Ortho (a
manufacturer of atypical antipsychotics) issued a warning to
Canadian clinicians of a possible link between risperidone use
and cerebrovascular adverse events.7 This concern emerged
from a clinical trial evaluating risperidone in the management of
BPSD,8 and a subsequent meta-analysis of the risperidone trials
for this indication also showed more cerebrovascular adverse
events among participants receiving risperidone (4%) than
among participants receiving placebo (2%).9 The US Food and
Drug Administration issued a similar warning in April 2003.10
More recently, pooled data from clinical trials evaluating olanza-
pine for BPSD have shown that it may also be associated with an
increased risk of cerebrovascular adverse events.11 12 These data
suggest around a threefold increase in the relative risk of
cerebrovascular events among people taking risperidone or
olanzapine. Based on these data, the UK Committee on Safety of
Medicines issued a warning in March 2004 advising that risperi-
done and olanzapine should no longer be used to manage
BPSD, and that patients already receiving these drugs for BPSD
should be switched to other treatments.12 These warnings have
led to controversy among clinicians.13 14 To date, the warnings
only extend to older adults receiving atypical antipsychotics for
BPSD and not to patients receiving these drugs for
schizophrenia or other indications. No warnings have been
issued on the use of other atypical agents, such as quetiapine or
aripiprazole, as few studies have been published on their use to
manage BPSD. Recent data from a clinical trial of quetiapine to
treat BPSD show no increased risk of cerebrovascular adverse
events compared with placebo.15
The potential link between atypical antipsychotics and
cerebrovascular adverse events in patients with BPSD is
important, given the common use of these drugs in this patient
population. If atypical antipsychotics are thought unsafe,
clinicians may consider using typical antipsychotics to treat
BPSD. We compared the incidence of admissions to hospitals for
stroke among older adults with dementia who received atypical
or typical antipsychotics.
Methods
From administrative healthcare databases in Ontario, Canada,
we identified older adults with a diagnosis of dementia and with
no history of antipsychotic drug use. In Ontario, a universally
funded health programme covers most doctor services, drugs,
and hospital services for patients aged 65 and older. We used
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encrypted unique identifiers that are common between the data-
bases to link anonymous information on personal details and
use of health services for patients in our study. The linked data-
bases included computerised pharmacy records of the Ontario
Drug Benefit Database, which records prescription drugs
dispensed to all Ontario residents aged 65 years or older.
Records for admission to hospital for acute care were obtained
from the Canadian Institute for Health Information Discharge
Abstract Database, which uses nomenclature from the ICD-9
(international classification of diseases, 9th revision) to provide
detailed diagnostic records for all hospital admissions. We
obtained information on doctors’ billing for inpatient and
outpatient services from the records of the Ontario Health
Insurance Plan, and basic personal information and vital
statistics for each patient from the Registered Persons Database.
Cohort
We identified two cohorts within the population of older adults
with dementia (Ontario Health Insurance Plan and ICD-9 codes
290, 331, and 797): those who were new users of any of three
atypical antipsychotics (risperidone, olanzapine, and quetiapine)
and those who were new users of either high potency typical
antipsychotics or low potency typical antipsychotics. Typical
antipsychotics included in this analysis were haloperidol,
fluphenazine, thiothixene, pimozide, trifluoperazine, flupen-
thixol, zuclopenthixol, thioproperazine, chlorpromazine, thiori-
dazine, mesoridazine, loxapine, perphenazine, promazine,
pericyazine, and chlorprothixane. We excluded patients who
were receiving non-oral antipsychotics (for example, injectable
or depot preparations), and patients with other psychotic
disorders such as schizophrenia that might affect their pattern of
drug use. The atypical antipsychotic clozapine was not
commonly used in Ontario during the period under study, and
we therefore excluded patients who were taking this drug. Other
atypical antipsychotics (including aripiprazole and ziprasidone)
are not currently licensed for use in Canada. We did not include
a cohort of non-antipsychotic users, as preliminary data show
several important baseline differences between patients receiving
antipsychotics and those not receiving antipsychotics.We did not
include cohorts of patients taking other psychotropics for BPSD,
such as trazadone or valproate, as these are also used for other
indications.
Patient observation
We enrolled patients into the cohorts between 1 April 1997 and
31 March 2002. To restrict our cohorts to new users of
antipsychotics, we looked back one year from the first date the
antipsychotic was dispensed to ensure that no such drugs had
been previously prescribed. We considered that exposure to the
antipsychotic had stopped if no further data on a dispensed drug
were recorded in the Ontario Drug Benefit Database within a
period of two times the total days supplied for the initial date the
drug was dispensed. This implied that patients were no longer
taking the antipsychotic.
Ischaemic stroke
Our primary outcome was admission to hospital with a most
responsible diagnosis of ischaemic stroke (ICD-9 codes 431, 434,
and 436). Validation studies have established an accuracy rate of
90% for the diagnosis of stroke based on these codes.16 Most
responsible diagnosis refers to the single most important condi-
tion responsible for admission. It is a term used by trained
abstractors who complete data collection for the Canadian Insti-
tute for Health Information to distinguish between the main rea-
son for admission and comorbid conditions. We were therefore
able to distinguish between old strokes and new outcome events.
Although the concerns surrounding atypical antipsychotics
involve cerebrovascular adverse events, including both transient
ischaemic attacks and stroke, we focused exclusively on the out-
come of stroke for several reasons: firstly, the diagnostic accuracy
for transient ischaemic attacks is relatively poor in administrative
databases; secondly, comparatively few patients with transient
ischaemic attacks are admitted to hospital; and, thirdly, the risk of
stroke in the period immediately after a transient ischaemic
attack is high, suggesting that we might capture subsequent
events with the coding for stroke.17–20
Patients were observed until they were admitted to hospital
with ischaemic stroke, stopped taking their antipsychotic, died, or
the study ended (31 March 2002). Patients in the cohort receiv-
ing atypical antipsychotics were censored if they switched
between atypical antipsychotics, to allow us to assess hazards
associated with each of the three atypical drugs under study.
Patients in the cohort receiving typical antipsychotics were cen-
sored if they switched to atypical antipsychotics. The coding
accuracy of drug claims in the Ontario Drug Benefit Database is
excellent, with an error rate of only 0.7%.21
Statistical analysis
We first calculated crude incidence rates of stroke for the cohorts,
using the number of events per 1000 patient years. To examine
the independent effect of use of atypical antipsychotics on devel-
oping ischaemic stroke, we conducted survival analysis using Cox
proportional hazards models. The covariates in our models
included factors that would influence the development or the
recognition of incident ischaemic stroke.22 These factors include
age; sex; low income status; residence in long term care;
frequency of medical contact (number of physician claim days per
patient per year); medical conditions such as prior stroke, atrial
fibrillation, diabetes mellitus, acute myocardial infarction in the
past three months, congestive heart failure; and overall burden
from comorbid disease. As an overall measure of comorbidity, we
used the number of distinct drugs dispensed in the year before
entry to the cohort,23 a measure that performs as well as the
Charlson comorbidity index in risk adjustment.24 We also control-
led for the concomitant use of drugs that might influence the risk
of stroke or recognition (for example, antihypertensives,
angiotensin converting enzyme inhibitors, lipid lowering drugs,
antidiabetic drugs, and hormone replacement therapies). Finally,
given the duration of our study and the potential for changes in
patient care over this period, we controlled for year of entry to the
study. Analyses were performed with SAS for UNIX, version 8.2.
We then carried out subgroup analyses on selected
populations of the cohorts. This was done to examine subgroups
that either were similar to patients in the trials (for example,most
patients in the trials of atypical antipsychotics for managing
BPSD were in long term care25) or were at high risk of stroke (for
example, a history of prior stroke or atrial fibrillation). We also
examined the risks from use of individual atypical antipsychotic
drugs. Finally, we carried out a subgroup analysis of patients
enrolled between 1 April 2000 and 31 March 2002. This analysis
was done to address major shifts in the prescribing of atypical
antipsychotics and typical antipsychotics between 1997 and
2002.
Results
We identified 32 710 older adults with dementia (17 845
dispensed atypical antipsychotics and 14 865 dispensed typical
antipsychotics). The atypical antipsychotic cohort included
Papers
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13 503 (75.7%) patients receiving risperidone, 3459 (19.4%)
receiving olanzapine, and 883 (4.9%) receiving quetiapine. Table
1 lists the personal characteristics and comorbidities of patients
in both cohorts. In general, the cohorts had similar personal
details (standardised differences for most comparisons were
< 10%). Baseline characteristics were also similar for the subco-
horts taking high potency typical antipsychotics (57.1%) and low
potency typical antipsychotics (42.9%; data not shown). Between
1997 and 2002 a major shift took place towards increased
prescribing of atypical antipsychotics. Traditional risk factors for
ischaemic stroke, such as atrial fibrillation, hypertension,
diabetes, and prior stroke, were common among older adults
with dementia (table 1).
In the unadjusted and multivariate analyses, we found that
the risk of ischaemic stroke in older adults with dementia receiv-
ing atypical antipsychotics was not significantly different from
those receiving typical antipsychotics (unadjusted hazard ratio
1.06, 95% confidence interval 0.89 to 1.27; adjusted hazard ratio
1.01, 0.81 to 1.26; table 2).
The subgroup analyses were all consistent with the main
analysis as they showed no significant differences in the develop-
ment of stroke between the cohorts receiving atypical
antipsychotics and those receiving typical antipsychotics (table
3). The risk of stroke for patients receiving risperidone (adjusted
hazard ratio 1.04, 0.82 to 1.31), olanzapine (0.91, 0.62 to 1.32),
and quetiapine (0.78, 0.38 to 1.57) was not significantly different
from that of patients receiving typical antipsychotics. Patients
dispensed two or more consecutive prescriptions (chronic users)
of atypical antipsychotics were not at increased risk of stroke
compared with chronic users of typical antipsychotics. Finally,
the risk of stroke in the subgroup of patients enrolled between 1
April 2000 and 31 March 2002 was not significantly different
between those receiving atypical antipsychotics and those receiv-
ing typical antipsychotics (adjusted hazard ratio 0.98, 95% confi-
dence interval 0.65 to 1.47).
Discussion
In this population based cohort, older adults with behavioural
and psychological symptoms of dementia (BPSD) who received
atypical antipsychotic drugs seem to have a similar risk of admis-
sion to hospital for ischaemic stroke as those receiving typical
antipsychotic drugs. These findings are important because of the
frequency with which atypical antipsychotics are used to manage
BPSD.6 Our results may help to inform drug prescribing for this
group of patients.
Table 1 Personal characteristics and details of comorbidity in cohorts of older
adults (≥65 years) with dementia who received atypical antipsychotics or typical
antipsychotics. Values are numbers (percentages) unless stated otherwise
Characteristics
Atypical
antipsychotics
cohort
(n=17 845)
Typical
antipsychotics
cohort
(n=14 865)
Mean (SD) age (years) 82.5 (7.3) 82.7 (7.4)
Men 6431 (36.0) 5727 (38.5)
Long term care 8485 (47.5) 7682 (51.7)
Low income 6688 (37.5) 5807 (39.1)
Urban residence 2807 (15.7) 2673 (18.0)
Mean (SD) frequency of medical contact (days)* 33.3 (25.4) 34.3 (26.8)
Year of entry to cohort:
1997 598 (3.4) 5452 (36.7)
1998 1588 (8.9) 4570 (30.7)
1999 3696 (20.7) 2680 (18.0)
2000 5589 (31.3) 1321 (8.9)
2001 6374 (35.7) 842 (5.7)
Chronic users† 13792 (77.3) 9929 (66.8)
Overall comorbidity (Charlson comorbidity index score):
No prior admission to hospital 3969 (22.2) 3068 (20.6)
0 (prior admission with no comorbidities listed) 6824 (38.2) 5173 (34.8)
1 3439 (19.3) 3080 (20.7)
2 1795 (10.1) 1615 (10.9)
≥3 1818 (10.2) 1929 (13.0)
Conditions affecting risk of stroke:
Prior stroke 1330 (7.5) 1189 (8.0)
Atrial fibrillation 1992 (11.2) 1672 (11.2)
Hypertension 10894 (61.0) 8620 (58.0)
Diabetes mellitus 3404 (19.1) 2756 (18.5)
Acute myocardial infarction 396 (2.2) 391 (2.6)
Congestive heart failure 4582 (25.7) 4130 (27.8)
Endocarditis 2 (<0.1) 1 (<0.1)
Rheumatic heart disease 317 (1.8) 239 (1.6)
Malignant neoplasm 4771 (26.7) 4196 (28.2)
Procedures affecting risk of stroke:
Electrical cardioversion for atrial fibrillation in past 3 months 11 (0.1) 9 (0.1)
Coronary angiography or angioplasty in past 3 months 15 (0.1) 16 (0.1)
Carotid endarterectomy in past 3 months 4 (<0.1) 1 (<0.1)
Drug history and drugs affecting risk of stroke:
Mean (SD) total No of drugs per patient 8.7 (5.3) 8.5 (5.5)
Any psychotropic 10877 (61.0) 8731 (58.7)
Benzodiazepines 7367 (41.3) 6420 (43.2)
Warfarin 1582 (8.9) 1248 (8.4)
Antiplatelets:
Aspirin 2799 (15.7) 2324 (15.6)
Ticlopidine 304 (1.7) 263 (1.8)
Clopidogrel 130 (0.7) 22 (0.1)
Combined dipyridamole and aspirin 14 (0.1) 2 (<0.1)
Antihypertensives:
Diuretics 2154 (12.1) 1500 (10.1)
 blockers 2172 (12.2) 1594 (10.7)
Calcium channel blockers 3345 (18.7) 2545 (17.1)
Combination therapies 88 (0.5) 54 (0.4)
Angiotensin II receptor blockers 274 (1.5) 117 (0.8)
Angiotensin converting enzyme inhibitors 4697 (26.3) 3281 (22.1)
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors 1324 (7.4) 563 (3.8)
Antidiabetic drugs 2099 (11.8) 1681 (11.3)
Hormone replacement therapies:
Oestrogen 796 (4.5) 483 (3.2)
Tamoxifen 137 (0.8) 112 (0.8)
Raloxifene 8 (<0.1) 1 (<0.1)
*No of claim days to Ontario Health Insurance Plan per patient per year in year before entry
to cohort.
†≥2 consecutive prescriptions for antipsychotics.
‡Claim to Ontario drug benefit programme for any cholinesterase inhibitor (donepezil,
rivastigmine, or galantamine) in year before index (these drugs were first listed on
programme in June 1999).
Table 2 Event rates and hazard ratios for older adults with dementia
receiving atypical or typical antipsychotics
Main analysis (full cohorts)
Atypical antipsychotic
cohort (n=17 845)
Typical antipsychotic
cohort (n=14 865)
No (%) of new admissions for
ischaemic stroke
284 (1.6) 227 (1.5)
Mean (SD) duration of follow up (days) 227.2 (264.0) 250.1 (335.4)
Crude event rate (No of events per 1000
person years)*
25.5 22.3
Unadjusted hazard ratio (95% CI) 1.06 (0.89 to 1.27) 1.00
Adjusted hazard ratio (95% CI)† 1.01 (0.81 to 1.26) 1.00
*(No of events/total No of days per 365 days)×1000.
†Adjusted for age; sex; low income status; residence in long term care; frequency of medical
contact; year of entry to cohort; history of stroke in past five years; history of atrial fibrillation;
hypertension; diabetes mellitus; acute myocardial infarction in past three months; congestive
heart failure; number of distinct drugs; chronic use (≥2 consecutive prescriptions) of
antipsychotics; and baseline use of warfarin, antiplatelet drugs, antihypertensive drugs,
angiotensin converting enzyme inhibitors, lipid lowering drugs, antidiabetic drugs, and
hormone replacement therapy.
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The findings from our main analysis were consistent with
those for all subgroups we tested. The incidence rates for stroke
corresponded well with those reported by other investigators
and highlight the relatively high risk of ischaemic stroke among
older adults with dementia.26 We found higher incidence rates of
stroke in those subgroups with established risk factors for stroke,
such as atrial fibrillation and prior stroke, than in the main
analysis. In contrast, we found no increase in risk among chronic
users (two or more consecutive prescriptions) of atypical
antipsychotics, suggesting the absence of an association between
atypical antipsychotics and cerebrovascular events. In effect, with
increasing duration of exposure there seems to be no increased
risk of the outcome.
Several investigators found no association between use of
atypical antipsychotics and cerebrovascular events.27–29 In
addition, recent data from a trial evaluating quetiapine for BPSD
showed no increased risk of cerebrovascular adverse events
compared with placebo.15 Our large population based study sup-
ports these findings. In contrast, earlier clinical trials of
risperidone and olanzapine reported a link between use of atypi-
cal antipsychotics and cerebrovascular adverse events, including
ischaemic stroke.9 11 It could be speculated that in these trials
events other than transient ischaemic attacks and strokes were
classified as “cerebrovascular adverse events.” If atypical agents
do contribute to the risk of stroke, however, a plausible biological
rationale must exist. The risk seems to develop quickly (6-12
weeks in clinical trials), and thus it seems unlikely that the risk is
mediated through drug effects on risk factors such as glucose or
lipid metabolism. Similarly, drug induced atrial fibrillation would
be an unlikely explanation for such a rapid increase in the risk of
cerebrovascular adverse events. Potential mechanisms for
cerebrovascular events related to atypical antipsychotics might
include orthostatic hypotension in patients with pre-existing cer-
ebrovascular disease, which might lead to “watershed” strokes,14
and antipsychotic induced hyperprolactinaemia, which might
promote platelet aggregation.14 30 Others, however, have
reported that risperidone may inhibit platelet aggregation
(through serotonin receptor antagonism), rather than promote
it.31 Some observational data have shown that antipsychotics
might be associated with an increased risk of venous
thromboembolic disease32; arterial thrombosis such as stroke,
however, shares few risk factors with venous thrombosis. In sum-
mary, a clear biological rationale has not yet been identified for
an increased risk of stroke associated with use of atypical anti-
psychotics. The collection of data on “cerebrovascular adverse
events” may have been influenced by patients’ receipt of active
drug therapy or placebo in the clinical trials. For example, it is
possible that patients given antipsychotic treatment with relief of
psychoses might report more symptoms than patients given pla-
cebo.14
Limitations of study
Our study has several potential limitations. Firstly, our study was
observational, and although the baseline differences between
our cohorts were minor, we may not have been able to adjust
adequately for such differences. Important confounders may
also have been unmeasured and unrecognised. We tried to avoid
confounding by indication by specifically excluding data from
the period after the first warning of cerebrovascular adverse
events was issued (October 2002).7 Before this time, the choice
between typical antipsychotics and atypical antipsychotics was
not affected by concerns about such adverse events. A second
limitation is the possibility of ascertainment bias because some
strokes may not have been captured if they did not lead to
admission to hospital or if they led immediately to death. Despite
the potential for ascertainment bias, we kept our primary
outcome as admission to hospital for stroke given the accuracy
with which this diagnosis is captured in the data we used. We
believe that most strokes in this patient population would have
resulted in hospital admission. Thirdly, given the limitations of
the administrative data, we could not adjust for all of the impor-
tant factors affecting the risk of stroke, such as smoking history,
presence and severity of hypertension, lipid status, and specific
valvular heart conditions.
What do these results mean for clinical practice? Clinicians
managing patients with dementia who develop behavioural
disturbances should initially rule out underlying medical
illnesses or drugs that might predispose to delirium.33 If BPSD
is diagnosed, clinicians should initially consider non-
pharmacological harm reduction strategies such as education of
family members, ABC charting, and music therapy.3 If
pharmacotherapy is considered necessary, it should be tailored
to the individual. Our data show that the risk of ischaemic stroke
is similar for patients receiving atypical antipsychotics and those
receiving typical antipsychotics. Other potential risks of anti-
psychotics (for example, extrapyramidal symptoms, tardive
dyskinesia) should also be weighed against the benefits. A
Table 3 Event rates and hazard ratios for subgroup analyses of older adults
with dementia receiving atypical or typical antipsychotics
Characteristics
Atypical
antipsychotics cohort
Typical
antipsychotic cohort
History of stroke (n=1330) (n=1189)
No (%) of new admissions for ischaemic
stroke
103 (7.7) 75 (6.3)
Mean (SD) duration of follow up (days) 217.1 (251.8) 235.0 (336.2)
Crude event rate (No of events per 1000
person years)*
130.4 98.2
Unadjusted hazard ratio (95% CI) 1.18 (0.88 to 1.59) 1.00
Adjusted hazard ratio (95% CI)† 0.80 (0.55 to 1.16) 1.00
Long term care resident at baseline (n=8485) (n=7682)
No (%) of new admissions for ischaemic
stroke
124 (1.5) 98 (1.3)
Mean (SD) duration of follow up (days) 225.7 (267.2) 253.1 (336)
Crude event rate (No of events per 1000
person years)*
23.7 18.4
Unadjusted hazard ratio (95% CI) 1.18 (0.91 to 1.54) 1.00
Adjusted hazard ratio (95% CI)† 1.15 (0.82 to 1.60) 1.00
Chronic users‡ (n=13 792) (n=9929)
No (%) of new admissions for ischaemic
stroke
214 (1.6) 163 (1.6)
Mean (SD) duration of follow up (days) 280.6 (277.7) 352.7 (367.1)
Crude event rate (No of events per 1000
person years)*
20.2 17
Unadjusted hazard ratio (95% CI) 1.11 (0.91 to 1.37) 1.00
Adjusted hazard ratio (95% CI)† 0.89 (0.69 to 1.17) 1.00
History of atrial fibrillation (n=1992) (n=1672)
No (%) of admissions for ischaemic stroke 52 (2.6) 34 (2.0)
Mean (SD) duration of follow up (days) 195.6 (233.1) 195.6 (288.6)
Crude event rate (No of events per 1000
person years)*
48.8 38
Unadjusted hazard ratio (95% CI) 1.23 (0.79 to 1.89) 1.00
Adjusted hazard ratio (95% CI)† 1.23 (0.70 to 2.02) 1.00
*(No of events/total No of days per 365 days)×1000.
†Adjusted for age; sex; low income status; residence in long term care; frequency of medical
contact; year of entry to cohort; history of stroke in past five years; history of atrial fibrillation;
hypertension; diabetes mellitus; acute myocardial infarction in past 3 months; congestive
heart failure; number of distinct drugs; chronic use (≥2 consecutive prescriptions) of
antipsychotics; baseline use of warfarin, antiplatelet drugs, antihypertensives, angiotensin
converting enzyme inhibitors, lipid lowering drugs, antidiabetic drugs, and hormone
replacement therapy. Factors not included in risk adjustment when they were focus of
subgroups analysis were residence in long term care, history of stroke in past five years,
history of atrial fibrillation, and chronic use of antipsychotics.
‡≥2 consecutive prescriptions.
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working group of psychiatrists, general practitioners, and
geriatricians in the United Kingdom has developed guidelines
for the management of BPSD in people with a history of stroke
or transient ischaemic attack.34 Unfortunately, many of the alter-
natives to atypical antipsychotics for managing BPSD have
received only limited evaluation and have their own important
adverse event profiles.4 The US National Institute of Mental
Health is currently sponsoring the clinical antipsychotic trials of
intervention effectiveness (CATIE) Alzheimer’s disease trial,
which is a 36 week study comparing three atypical antipsychot-
ics, a selective serotonin reuptake inhibitor, and placebo to treat
BPSD. Results are due in 2006.35 This study and others36 should
shed light on the optimal management of BPSD and the risk of
stroke in this patient population.
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What is already known on this topic
Atypical antipsychotics are commonly used to manage
behavioural and psychological symptoms of dementia (BPSD)
Recent evidence from clinical trials suggests an association
between atypical antipsychotic use and cerebrovascular events
(including stroke) among older adults with BPSD
These data prompted the UK Committee on Safety of
Medicines to recommend against the prescribing of atypical
antipsychotics to patients with BPSD
What this study adds
Use of atypical antipsychotics by patients with dementia is not
associated with a greater risk of stroke is than use of typical
antipsychotics
Findings were consistent for a series of subgroup analyses
including ones for patients at high baseline risk of stroke
The choice of atypical or typical antipsychotics to manage
BPSD should not be based on concerns about the risk of
stroke
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